143 related articles for article (PubMed ID: 31486229)
1. Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer.
Gibson AJW; D'Silva A; Elegbede AA; Tudor RA; Dean ML; Bebb DG; Hao D
Asia Pac J Clin Oncol; 2019 Dec; 15(6):343-352. PubMed ID: 31486229
[TBL] [Abstract][Full Text] [Related]
2. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status.
Ou SH; Ziogas A; Zell JA
J Thorac Oncol; 2009 Sep; 4(9):1083-93. PubMed ID: 19652625
[TBL] [Abstract][Full Text] [Related]
3. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era.
Ahn MJ; Lee J; Park YH; Ahn JS; Ziogas A; Zell JA; Park K; Ou SH
J Thorac Oncol; 2010 Aug; 5(8):1185-96. PubMed ID: 20592628
[TBL] [Abstract][Full Text] [Related]
4. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases.
Kawaguchi T; Matsumura A; Fukai S; Tamura A; Saito R; Zell JA; Maruyama Y; Ziogas A; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 Jul; 5(7):1001-10. PubMed ID: 20526205
[TBL] [Abstract][Full Text] [Related]
5. Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.
Becker DJ; Wisnivesky JP; Grossbard ML; Chachoua A; Camidge DR; Levy BP
Clin Lung Cancer; 2017 Jan; 18(1):e35-e40. PubMed ID: 28029530
[TBL] [Abstract][Full Text] [Related]
6. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
[TBL] [Abstract][Full Text] [Related]
8. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
9. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
12. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
14. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese.
Matsuo K; Ito H; Yatabe Y; Hiraki A; Hirose K; Wakai K; Kosaka T; Suzuki T; Tajima K; Mitsudomi T
Cancer Sci; 2007 Jan; 98(1):96-101. PubMed ID: 17054433
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
[TBL] [Abstract][Full Text] [Related]
16. Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.
Tudor RA; D'Silva A; Tremblay A; MacEachern P; Morris D; Brenner D; Kopciuk K; Bebb DG
PLoS One; 2017; 12(8):e0181867. PubMed ID: 28777825
[TBL] [Abstract][Full Text] [Related]
17. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
[TBL] [Abstract][Full Text] [Related]
18. A comparison study of clinicopathologic characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) patients by smoking status.
Ou SH; Ziogas A; Zell JA
J Thorac Oncol; 2010 Feb; 5(2):158-68. PubMed ID: 20040896
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations.
Zeng Z; Chen HJ; Yan HH; Yang JJ; Zhang XC; Wu YL
Int J Biol Markers; 2013 Sep; 28(3):249-58. PubMed ID: 23873621
[TBL] [Abstract][Full Text] [Related]
20. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
